CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published ahead of print on March 11, 2009
Clin J Am Soc Nephrol 4: 734-744, 2009
© 2009 American Society of Nephrology
doi: 10.2215/CJN.05231008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
CJN.05231008v1
4/4/734    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bomback, A. S.
Right arrow Articles by Nachman, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bomback, A. S.
Right arrow Articles by Nachman, P. H.

Clinical Nephrology

Rituximab Therapy for Membranous Nephropathy: A Systematic Review

Andrew S. Bomback, Vimal K. Derebail, Julie G. McGregor, Abhijit V. Kshirsagar, Ronald J. Falk, and Patrick H. Nachman

University of North Carolina Kidney Center, Department of Medicine, Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Correspondence: Dr. Andrew S. Bomback, University of North Carolina Kidney Center, 7011-E Burnett-Womack Building, Campus Box 7155, Chapel Hill, NC 27599-7155. Phone: 919-966-2561; Fax: 919-966-4251; E-mail: abomback{at}unch.unc.edu

Background and objectives: The treatment of membranous nephropathy (MN) remains controversial. Rituximab, which selectively targets B cells, has emerged as a possible alternative treatment option with limited toxicity.

Design, setting, participants, & measurements: The available data on rituximab therapy for MN were reviewed using the MEDLINE database (inception to August 1, 2008), Google Scholar, and selected reference lists. English-language studies investigating the use of rituximab in idiopathic and secondary MN, in native and transplanted kidneys, were included. Study design, subject number, clinical characteristics (diagnosis, previous and concomitant treatment courses, baseline proteinuria, baseline renal function), rituximab protocol, follow-up period, achievement of complete or partial remission, changes in proteinuria and renal function, and adverse effects of therapy were extracted.

Results: Twenty-one articles were included for review; all were either case reports or case series without controls. More than half of the published cases (50 of 85) came from one center where rituximab was used as primary immunosuppression for idiopathic MN. The available data suggest that rituximab, dosed either as 375 mg/m2 once weekly for 4 wk or as 1 g on days 1 and 15, achieves a 15 to 20% rate of complete remission and a 35 to 40% rate of partial remission. The drug was well tolerated with minimal adverse events.

Conclusions: Although rituximab may prove to be a better treatment option for MN than alkylating agents or calcineurin inhibitors, the current literature only supports using the drug in research protocols. Whether, when, how, and why to use rituximab in MN remains to be determined.




This article has been cited by other articles:


Home page
 CJASNHome page
F. Vincenti, S. D. Cohen, and G. Appel
Novel B Cell Therapeutic Targets in Transplantation and Immune-Mediated Glomerular Diseases
Clin. J. Am. Soc. Nephrol., January 1, 2010; 5(1): 142 - 151.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Society of Nephrology.